Microcin MccI47 selectively inhibits enteric bacteria and reduces carbapenem-resistant <i>Klebsiella pneumoniae</i> colonization <i>in vivo</i> when administered <i>via</i> an engineered live biotherapeutic
Benedikt M. Mortzfeld, Jacob D. Palmer, Shakti K. Bhattarai, Haley L. Dupre, Regino Mercado-Lubio, Mark W. Silby, Corinna Bang, Beth A. McCormick, Vanni Bucci
Abstract
in a preclinical animal model, when delivered from an engineered live biotherapeutic product. This study serves as the foundational step toward the use of engineered live biotherapeutic products aimed at the selective removal of MDR pathogens from the GI tract.
Topics & Concepts
Klebsiella pneumoniaeMicrobiologyBiologyPlasmidEnterobacteriaceaeEscherichia coliAntibioticsAntimicrobialCarbapenemBacteriaAntibiotic resistanceMultiple drug resistanceGeneBiochemistryGeneticsAntibiotic Resistance in BacteriaBacteriophages and microbial interactionsProbiotics and Fermented Foods